Estrella Immunopharma, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Estrella Immunopharma, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.06M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($4.43M) | Mar 18, 2026 |
| FY2024 | Jun 30, 2024 | ($7.31M) | Sep 27, 2024 |
| FY2024 | Jun 30, 2023 | ($11.11M) | Sep 27, 2024 |
| FY2022 | Dec 31, 2022 | ($996.1K) | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | ($247.7K) | Mar 14, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.06M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($4.43M) | Mar 18, 2026 |
| FY2024 | Jun 30, 2024 | ($7.31M) | Sep 27, 2024 |
| FY2024 | Jun 30, 2023 | ($11.11M) | Sep 27, 2024 |
| FY2022 | Dec 31, 2022 | ($1.57M) | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | ($249.1K) | Mar 14, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.25M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $2.86M | Mar 18, 2026 |
| FY2024 | Jun 30, 2024 | $4.11M | Sep 27, 2024 |
| FY2024 | Jun 30, 2023 | $10.45M | Sep 27, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.79M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($3.11M) | Mar 18, 2026 |
| FY2024 | Jun 30, 2024 | ($16.07M) | Sep 27, 2024 |
| FY2024 | Jun 30, 2023 | ($1.34M) | Sep 27, 2024 |
| FY2022 | Dec 31, 2022 | ($1.04M) | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | ($316.2K) | Mar 14, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.18M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $3.14M | Mar 18, 2026 |
| FY2024 | Jun 30, 2024 | $4.45M | Sep 27, 2024 |
| FY2024 | Jun 30, 2023 | $3.03M | Sep 27, 2024 |
| FY2022 | Dec 31, 2022 | $9.72M | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | $45.80M | Mar 14, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.54M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $3.00M | Mar 18, 2026 |
| FY2024 | Jun 30, 2024 | $180.7K | Sep 27, 2024 |
| FY2024 | Jun 30, 2023 | $9.77M | Sep 27, 2024 |
| FY2022 | Dec 31, 2022 | $2.65M | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | $1.62M | Mar 14, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.37M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $143.7K | Mar 18, 2026 |
| FY2025 | Jun 30, 2024 | $4.27M | Mar 18, 2026 |
| FY2024 | Jun 30, 2023 | ($11.74M) | Sep 27, 2024 |
| FY2022 | Dec 31, 2022 | ($2.26M) | Mar 14, 2023 |
| FY2024 | Jun 30, 2022 | ($1.04M) | Sep 27, 2024 |
| FY2022 | Dec 31, 2021 | ($1.01M) | Mar 14, 2023 |
| FY2022 | Jan 5, 2021 | $0 | Mar 14, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($36.99M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($23.93M) | Mar 18, 2026 |
| FY2024 | Jun 30, 2024 | ($19.50M) | Sep 27, 2024 |
| FY2024 | Jun 30, 2023 | ($12.19M) | Sep 27, 2024 |
| FY2022 | Dec 31, 2022 | ($2.26M) | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | ($1.01M) | Mar 14, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.38M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $916.9K | Mar 18, 2026 |
| FY2024 | Jun 30, 2024 | $4.17M | Sep 27, 2024 |
| FY2024 | Jun 30, 2023 | $2.48M | Sep 27, 2024 |
| FY2022 | Dec 31, 2022 | $40.8K | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | $478.9K | Mar 14, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 18, 2026 |
| FY2024 | Jun 30, 2024 | 0 | Sep 27, 2024 |
| FY2024 | Jun 30, 2023 | (36) | Sep 27, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 18, 2026 |
| FY2024 | Jun 30, 2024 | 0 | Sep 27, 2024 |
| FY2024 | Jun 30, 2023 | (36) | Sep 27, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | 36.61M | Sep 27, 2024 |
| FY2024 | Jun 30, 2023 | 978,243 | Sep 27, 2024 |
| FY2022 | Dec 31, 2022 | 1.42M | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | 1.42M | Mar 14, 2023 |
| FY2021 | Mar 31, 2021 | 1.42M | Mar 29, 2022 |
| FY2021 | Jan 31, 2021 | 1.42M | Mar 29, 2022 |